Robert Azelby - 13 Jun 2024 Form 4 Insider Report for ADC Therapeutics SA (ADCT)

Reporting relationship: Director
Issuer ticker: ADCT
Reported as of: 13 Jun 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Jun 2024, 17:46:59 UTC
Prior SEC filing: 18 Mar 2024
Next SEC filing: 18 Jun 2024
Source filing: View source filing
Reporting owner signature: Lisa Kallebo, as Attorney-in-Fact for Robert Azelby

Key filing fact

Robert Azelby filed Form 4 for ADC Therapeutics SA (ADCT) on 14 Jun 2024.

Key facts

This page summarizes Robert Azelby's Form 4 filing for ADC Therapeutics SA (ADCT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 Jun 2024, 17:46.

Change

Previous filing in this sequence was filed on 18 Mar 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADCT transaction

Common Shares

Award

Transaction value: $0
Shares: +40,000
Change %: +200%
Price: $0.000000
Shares after: 60,000
Date: 13 Jun 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents the annual grant of restricted stock units ("RSUs") made under the Issuer's 2019 Equity Incentive Plan for service as a Director. The RSUs vest one year from the grant date, subject to the Reporting Person's continued service to the Issuer. Each RSU represents a contingent right to receive one share of the Issuer's common stock.